Background Statins reduce LDL cholesterol and cardiovascular events among those with or
without diabetes but have been reported to increase new-onset diabetes. The CLEAR …

Aim To evaluate the effect of bempedoic acid on glycaemic and lipid variables in patients
with hypercholesterolaemia. Methods A patient‐level pooled analysis of four phase 3 …

Background Bempedoic acid is an oral, once-daily, first-in-class drug being developed for
the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the …

Introduction Bempedoic acid is a new agent that reduces low-density lipoprotein cholesterol.
Since inhibits cholesterol synthesis through a different mechanism than statins, the adverse …

Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …

Objectives Bempedoic acid (BA) is a novel oral low-density lipoprotein cholesterol lowering
drug. This systematic review and meta-analysis aims to assess efficacy and safety for clinical …

Importance The ATP citrate lyase (ACL) inhibitor, bempedoic acid, reduces low-density
lipoprotein cholesterol (LDL-C) level and major adverse cardiovascular events (MACE) by …

Importance Additional lipid-lowering therapy options are needed for patients who cannot
achieve sufficient decreases in low-density lipoprotein cholesterol (LDL-C) levels using …

Aims Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular
mortality and morbidity. Bempedoic acid represents a promising novel lipid-modifying agent …

Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA
and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation …